Clinical Trial

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

Study acronym: CD7-CAR01
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-26; most recent amendment 2025-11-25.
Status change: Not Yet Recruiting → Recruiting 2024-05-28
Trial Details
NCT Number NCT06064903
Lead Sponsor Bambino Gesù Hospital and Research Institute
Conditions T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Enrollment 26 participants
Start Date 2024-04-21
Primary Completion 2028-09-30 (estimated)
Study Completion 2040-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-02